These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 1389522)
21. Laparotomy-staged IA versus IIA Hodgkin's disease. A comparative study with evaluation of prognostic factors for stage IIA disease. Zagars G; Rubin P Cancer; 1985 Aug; 56(4):864-73. PubMed ID: 4016677 [TBL] [Abstract][Full Text] [Related]
22. Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. Horwich A; Specht L; Ashley S Eur J Cancer; 1997 May; 33(6):848-53. PubMed ID: 9291804 [TBL] [Abstract][Full Text] [Related]
23. The optimal dose of radiation in Hodgkin's disease: an analysis of clinical and treatment factors affecting in-field disease control. Mendenhall NP; Rodrigue LL; Moore-Higgs GJ; Marcus RB; Million RR Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):551-61. PubMed ID: 10348284 [TBL] [Abstract][Full Text] [Related]
25. Pelvic relapse following subtotal lymphoid irradiation in early stage Hodgkin's disease--an analysis of risk, management, and outcome. Tate DJ; Hoppe RT Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):1239-44. PubMed ID: 7607947 [TBL] [Abstract][Full Text] [Related]
26. Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial. Mauch PM; Canellos GP; Shulman LN; Silver B; Tarbell NJ; Come S; Rabin MS; Coleman CN J Clin Oncol; 1995 Apr; 13(4):947-52. PubMed ID: 7707123 [TBL] [Abstract][Full Text] [Related]
27. Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria. Ha CS; Kavadi V; Dimopoulos MA; Hagemeister FB; Osborne BM; Fuller LM; Smith TL; Hess MA; McLaughlin PW; Cabanillas FF; Cox JD Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):329-34. PubMed ID: 10030257 [TBL] [Abstract][Full Text] [Related]
28. Late relapse after treatment for clinical stage I and II Hodgkin's disease. Brierley JD; Rathmell AJ; Gospodarowicz MK; Sutcliffe SB; Pintillie M Cancer; 1997 Apr; 79(7):1422-7. PubMed ID: 9083165 [TBL] [Abstract][Full Text] [Related]
29. Non-Hodgkin's lymphoma of the thyroid gland: prognostic factors and treatment outcome. The Princess Margaret Hospital Lymphoma Group. Tsang RW; Gospodarowicz MK; Sutcliffe SB; Sturgeon JF; Panzarella T; Patterson BJ Int J Radiat Oncol Biol Phys; 1993 Oct; 27(3):599-604. PubMed ID: 8226154 [TBL] [Abstract][Full Text] [Related]
30. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. Chen RC; Chin MS; Ng AK; Feng Y; Neuberg D; Silver B; Pinkus GS; Stevenson MA; Mauch PM J Clin Oncol; 2010 Jan; 28(1):136-41. PubMed ID: 19933914 [TBL] [Abstract][Full Text] [Related]
31. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. Dühmke E; Franklin J; Pfreundschuh M; Sehlen S; Willich N; Rühl U; Müller RP; Lukas P; Atzinger A; Paulus U; Lathan B; Rüffer U; Sieber M; Wolf J; Engert A; Georgii A; Staar S; Herrmann R; Beykirch M; Kirchner H; Emminger A; Greil R; Fritsch E; Koch P; Drochtert A; Brosteanu O; Hasenclever D; Loeffler M; Diehl V J Clin Oncol; 2001 Jun; 19(11):2905-14. PubMed ID: 11387364 [TBL] [Abstract][Full Text] [Related]
32. Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation. Coleman M; Kaufmann T; Nisce LZ; Leonard JP Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1235-8. PubMed ID: 10725636 [TBL] [Abstract][Full Text] [Related]
33. Stage IA to IIB supradiaphragmatic Hodgkin's disease. Long-term survival and relapse frequency. Leslie NT; Mauch PM; Hellman S Cancer; 1985 May; 55(9 Suppl):2072-8. PubMed ID: 3919921 [TBL] [Abstract][Full Text] [Related]
34. Pathologic stages IA and IIA Hodgkin's disease: results of treatment with radiotherapy alone (1968-1980). Cornbleet MA; Vitolo U; Ultmann JE; Golomb HM; Oleske D; Griem ML; Ferguson DJ; Miller JB J Clin Oncol; 1985 Jun; 3(6):758-68. PubMed ID: 4009215 [TBL] [Abstract][Full Text] [Related]
35. Extended-field radiotherapy in favorable stage IA-IIA Hodgkin's disease (prognostic role of stage). Zanini M; Viviani S; Santoro A; Soncini F; Bonfante V; Devizzi L; Villani F; Castellani MR; Negretti E; Zucali R Int J Radiat Oncol Biol Phys; 1994 Nov; 30(4):813-9. PubMed ID: 7525516 [TBL] [Abstract][Full Text] [Related]
36. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. Biti GP; Cimino G; Cartoni C; Magrini SM; Anselmo AP; Enrici RM; Bellesi GP; Bosi A; Papa G; Giannarelli D J Clin Oncol; 1992 Mar; 10(3):378-82. PubMed ID: 1740677 [TBL] [Abstract][Full Text] [Related]
37. Long-term results of 60 patients with pathologic stage I & IIA Hodgkin's disease treated with exclusive mantle radiation therapy. Enrici RM; Osti MF; Zurlo A; Anselmo AP; Iacari V; Mandelli F Eur J Haematol; 1999 Aug; 63(2):126-33. PubMed ID: 10480292 [TBL] [Abstract][Full Text] [Related]